Oral Drugs for Benign Prostatic Hyperplasia Market 2022: Industry Size, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2028
Oral Drugs for Benign Prostatic Hyperplasia Market 2022: Industry Size, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2028
Analysis of the Oral Drugs for Benign Prostatic Hyperplasia Market reveals emerging trends, consumer adoption rates, and competitive strategies among leading manufacturers worldwide.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report aims to provide a comprehensive presentation of the global market for Oral Drugs for Benign Prostatic Hyperplasia study by Market Intellix gives insights concerning the market elements influencing the market, Market scope, Market division, and overlays shadow upon the leading market players featuring the positive cutthroat scene and patterns beating the years.
Global Oral Drugs for Benign Prostatic Hyperplasia Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oral Drugs for Benign Prostatic Hyperplasia companies in 2021 (%)
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alpha Blockers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
The study provides the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Segmental Outline:
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2021 (%)
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2021 (%)
Hospitals
Drugstores
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2021 (%)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
This Report Addresses:
– Market Intelligence enables effective decision-making
– Market estimates and forecasts from 2022 to 2028
– Growth opportunities and trend analysis
– Segment and regional revenue forecast for market evaluation
– Competitive strategy and analysis of market segments
– List of product innovations to stay on top.
– The impact of COVID-19 and how to survive in these fast-growing markets.
1 Introduction to Research & Analysis Reports
1.1 Oral Drugs for Benign Prostatic Hyperplasia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral Drugs for Benign Prostatic Hyperplasia Overall Market Size
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2021 VS 2028
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales: 2017-2028
3 Company Landscape
3.1 Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.2 Top Global Oral Drugs for Benign Prostatic Hyperplasia Companies Ranked by Revenue
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies
3.4 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies
3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Oral Drugs for Benign Prostatic Hyperplasia Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.8.1 List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies
3.8.2 List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Markets, 2021 & 2028
4.1.2 Alpha Blockers
4.1.3 5-alpha Reductase Inhibitors
4.1.4 Others
4.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
4.2.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
4.2.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
4.2.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
4.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
4.3.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
4.3.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
4.3.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
4.4 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
5.2.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
5.2.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
5.2.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
5.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
5.3.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
5.3.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
5.3.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
5.4 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2021 & 2028
6.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
6.2.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
6.2.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
6.2.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
6.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
6.3.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
6.3.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
6.3.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.4.2 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.4.3 US Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.4.4 Canada Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.4.5 Mexico Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.5.2 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.5.3 Germany Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.4 France Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.5 U.K. Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.6 Italy Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.7 Russia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.8 Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.9 Benelux Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.6.2 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.6.3 China Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.4 Japan Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.5 South Korea Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.6 Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.7 India Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.7.2 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.7.3 Brazil Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.7.4 Argentina Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.8.3 Turkey Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.4 Israel Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.5 Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.6 UAE Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Corporate Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.1.5 Eli Lilly Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.2.5 GlaxoSmithKline Key News
7.3 Astellas Pharma
7.3.1 Astellas Pharma Corporate Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.3.5 Astellas Pharma Key News
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.4.5 Sanofi Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.5.5 Pfizer Key News
7.6 Abbott
7.6.1 Abbott Corporate Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.6.5 Abbott Key News
7.7 Allergan
7.7.1 Allergan Corporate Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.7.5 Allergan Key News
7.8 TEVA
7.8.1 TEVA Corporate Summary
7.8.2 TEVA Business Overview
7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.8.5 TEVA Key News
7.9 Viatris
7.9.1 Viatris Corporate Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.9.5 Viatris Key News
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.10.5 Novartis Key News
7.11 Merck
7.11.1 Merck Corporate Summary
7.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Business Overview
7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.11.5 Merck Key News
8 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, Analysis
8.1 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, 2017-2028
8.2 Oral Drugs for Benign Prostatic Hyperplasia Production Capacity of Key Manufacturers in Global Market
8.3 Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oral Drugs for Benign Prostatic Hyperplasia Supply Chain Analysis
10.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
10.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Market
10.3 Oral Drugs for Benign Prostatic Hyperplasia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Research Methodology:
Oral Drugs for Benign Prostatic Hyperplasia Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|